(New York, NY) – December 9, 2013 – Ai Cure Technologies, an artificial intelligence company providing advanced facial recognition solutions to monitor medication adherence, presented at the 2013 MHealth Summit in Washington, D.C. on December 9, 2013. Ai Cure showcased AiViewTM as one of the very few technologies able to accurately confirm patient medication administration and offer a viable and cost-effective alternative to DOT. Unlike other technologies such as smart pills or hardware designed to measure medication in a patient’s breath, AiViewTM uses facial recognition software that is available as an app, requiring no additional changes to the drug manufacturing process or additional hardware. AiViewTM is designed for disease categories requiring DOT or high levels of monitoring, where non-adherence is particularly costly. The technology is also used in clinical research in life sciences as a risk-mitigation solution.
Jan 31, 2023
PTSD Study Uses Precision Medicine Tech from AiCure
Jan 07, 2023
Trendspotting: Hybrid and Decentralized Clinical Trials, Patient-Centricity, and Increased Remote Patient Monitoring in 2023
Dec 05, 2022
Open-Source AI Platforms: The Next Frontier in Health Innovation
- Jan 31, 2023